Menu
GeneBe

GJB1

gap junction protein beta 1, the group of Gap junction proteins

Basic information

Region (hg38): X:71212810-71225516

Previous symbols: [ "CMTX1", "CMTX" ]

Links

ENSG00000169562NCBI:2705OMIM:304040HGNC:4283Uniprot:P08034AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • Charcot-Marie-Tooth disease X-linked dominant 1 (Moderate), mode of inheritance: XL
  • Charcot-Marie-Tooth disease X-linked dominant 1 (Strong), mode of inheritance: XL
  • X-linked progressive cerebellar ataxia (Supportive), mode of inheritance: XL
  • Charcot-Marie-Tooth disease X-linked dominant 1 (Supportive), mode of inheritance: XL
  • Charcot-Marie-Tooth disease X-linked dominant 1 (Definitive), mode of inheritance: XL

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Charcot-Marie-Tooth neuropathy, X-linked dominant, 1XLGeneralGenetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testingNeurologic8266101; 10487913; 17100997; 17353473; 21254193; 21504505; 21692908; 21922480; 21692908; 22483671; 22577229

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the GJB1 gene.

  • Charcot-Marie-Tooth Neuropathy X (410 variants)
  • Charcot-Marie-Tooth disease (173 variants)
  • not provided (147 variants)
  • Charcot-Marie-Tooth disease X-linked dominant 1 (122 variants)
  • Inborn genetic diseases (43 variants)
  • not specified (29 variants)
  • Peripheral neuropathy (4 variants)
  • GJB1-related condition (2 variants)
  • Cerebellar ataxia (1 variants)
  • D-2-hydroxyglutaric aciduria 1 (1 variants)
  • GJB1-related disorders (1 variants)
  • Charcot-Marie-Tooth disease-hearing loss-intellectual disability syndrome (1 variants)
  • Pes cavus;Hammertoe;Distal muscle weakness;Decreased nerve conduction velocity;Sensory neuropathy (1 variants)
  • Hand muscle atrophy;Peroneal muscle atrophy;Pes cavus;Distal lower limb muscle weakness (1 variants)
  • Dejerine-Sottas disease (1 variants)
  • 8 conditions (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the GJB1 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
78
clinvar
5
clinvar
83
missense
47
clinvar
77
clinvar
164
clinvar
3
clinvar
1
clinvar
292
nonsense
20
clinvar
2
clinvar
1
clinvar
23
start loss
2
clinvar
2
clinvar
4
frameshift
34
clinvar
5
clinvar
39
inframe indel
1
clinvar
8
clinvar
9
splice donor/acceptor (+/-2bp)
1
clinvar
2
clinvar
3
splice region
1
1
2
non coding
1
clinvar
10
clinvar
4
clinvar
5
clinvar
20
Total 104 88 185 85 11

Highest pathogenic variant AF is 0.00000909

Variants in GJB1

This is a list of pathogenic ClinVar variants found in the GJB1 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
X-71215290-G-C Uncertain significance (Jan 01, 2018)547085
X-71222995-G-A not specified • Charcot-Marie-Tooth Neuropathy X Benign (Jan 22, 2024)255410
X-71223079-C-T Likely benign (Oct 21, 2018)1203086
X-71223112-T-G Uncertain significance (Dec 01, 2023)1676171
X-71223168-C-G Charcot-Marie-Tooth Neuropathy X Conflicting classifications of pathogenicity (Jun 02, 2023)406227
X-71223169-AAAGG-CAAGT Uncertain significance (May 15, 2017)429946
X-71223179-T-C Charcot-Marie-Tooth Neuropathy X Pathogenic (Jan 04, 2024)543921
X-71223179-T-G Charcot-Marie-Tooth disease X-linked dominant 1 Pathogenic (Nov 15, 2001)10445
X-71223181-G-C Charcot-Marie-Tooth disease X-linked dominant 1 Pathogenic (Nov 01, 2004)10449
X-71223181-G-T Charcot-Marie-Tooth Neuropathy X Uncertain significance (Aug 31, 2023)2033849
X-71223217-C-G Charcot-Marie-Tooth disease X-linked dominant 1 Uncertain significance (-)972701
X-71223224-G-A Charcot-Marie-Tooth disease X-linked dominant 1 Uncertain significance (Jan 12, 2018)368623
X-71223243-C-T GJB1-related disorder Likely benign (Jul 11, 2019)3049465
X-71223249-C-T Charcot-Marie-Tooth disease X-linked dominant 1 • Charcot-Marie-Tooth Neuropathy X • Charcot-Marie-Tooth disease Pathogenic/Likely pathogenic (Mar 15, 2024)217166
X-71223250-G-A Charcot-Marie-Tooth disease X-linked dominant 1 Uncertain significance (Mar 30, 2018)913594
X-71223251-C-T not specified • GJB1-related disorder Conflicting classifications of pathogenicity (Feb 28, 2023)380606
X-71223275-G-A not specified Benign/Likely benign (Dec 22, 2016)384473
X-71223307-G-T Uncertain significance (Jul 15, 2022)1807291
X-71223325-C-T not specified Conflicting classifications of pathogenicity (Dec 12, 2017)246214
X-71223335-G-A Charcot-Marie-Tooth Neuropathy X • Charcot-Marie-Tooth disease X-linked dominant 1 Pathogenic/Likely pathogenic (Jan 08, 2024)246014
X-71223337-T-G Charcot-Marie-Tooth Neuropathy X Uncertain significance (Nov 05, 2023)2772907
X-71223345-C-A Uncertain significance (Jul 01, 2020)995075
X-71223451-C-T not specified Benign (Mar 01, 2016)380814
X-71223610-G-C Likely benign (Sep 01, 2018)1203066
X-71223642-CTTTCCACCCCAGCTTTCTGACAGCTTGCTTCATGGCTGGTGTTTTGCAGGTGTGAATGAGGCAGGATGAACTGGACAGGTTTGTACACCTTGCTCAGTGGCGTGAACCGGCATTCTACTGCCATTGGCCGAGTATGGCTCTCGGTCATCTTCATCTTCAGAATCATGGTGCTGGTGGTGGCTGCAGAGAGTGTGTGGGGTGATGAGAAATCTTCCTTCATCTGCAACACACTCCAGCCTGGCTGCAACAGCGTTTGCTATGACCAATTCTTCCCCATCTCCCATGTGCGGCTGTGGTCCCTGCAGCTCATCCTAG-C Charcot-Marie-Tooth Neuropathy X Pathogenic (Apr 19, 2023)2857643

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
GJB1protein_codingprotein_codingENST00000374022 110323
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.8460.15100000.00
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense2.03661310.5020.00001171828
Missense in Polyphen1054.8090.18245839
Synonymous0.4134952.80.9280.00000445604
Loss of Function2.3006.150.005.38e-782

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.000.00
Ashkenazi Jewish0.000.00
East Asian0.000.00
Finnish0.000.00
European (Non-Finnish)0.000.00
Middle Eastern0.000.00
South Asian0.000.00
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell.;
Disease
DISEASE: Charcot-Marie-Tooth disease, X-linked dominant, 1 (CMTX1) [MIM:302800]: A form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies characterized by severely reduced motor nerve conduction velocities (NCVs) (less than 38m/s) and segmental demyelination and remyelination, and primary peripheral axonal neuropathies characterized by normal or mildly reduced NCVs and chronic axonal degeneration and regeneration on nerve biopsy. CMTX1 has both demyelinating and axonal features. Central nervous system involvement may occur. {ECO:0000269|PubMed:10071100, ECO:0000269|PubMed:10220155, ECO:0000269|PubMed:10234007, ECO:0000269|PubMed:10586284, ECO:0000269|PubMed:10732813, ECO:0000269|PubMed:10737979, ECO:0000269|PubMed:10873293, ECO:0000269|PubMed:10894999, ECO:0000269|PubMed:10923043, ECO:0000269|PubMed:10938190, ECO:0000269|PubMed:11030070, ECO:0000269|PubMed:11140841, ECO:0000269|PubMed:11180613, ECO:0000269|PubMed:11437164, ECO:0000269|PubMed:11438991, ECO:0000269|PubMed:11562788, ECO:0000269|PubMed:11571214, ECO:0000269|PubMed:11723288, ECO:0000269|PubMed:11835375, ECO:0000269|PubMed:11891346, ECO:0000269|PubMed:12185164, ECO:0000269|PubMed:12207932, ECO:0000269|PubMed:12325071, ECO:0000269|PubMed:12402337, ECO:0000269|PubMed:12477701, ECO:0000269|PubMed:12497641, ECO:0000269|PubMed:12536289, ECO:0000269|PubMed:12707076, ECO:0000269|PubMed:14627639, ECO:0000269|PubMed:15241803, ECO:0000269|PubMed:15468313, ECO:0000269|PubMed:15852376, ECO:0000269|PubMed:27234031, ECO:0000269|PubMed:7477983, ECO:0000269|PubMed:7833935, ECO:0000269|PubMed:8004109, ECO:0000269|PubMed:8162049, ECO:0000269|PubMed:8266101, ECO:0000269|PubMed:8628473, ECO:0000269|PubMed:8698335, ECO:0000269|PubMed:8733054, ECO:0000269|PubMed:8737658, ECO:0000269|PubMed:8807343, ECO:0000269|PubMed:8829637, ECO:0000269|PubMed:8889588, ECO:0000269|PubMed:8956046, ECO:0000269|PubMed:8990008, ECO:0000269|PubMed:9018031, ECO:0000269|PubMed:9099841, ECO:0000269|PubMed:9187667, ECO:0000269|PubMed:9272161, ECO:0000269|PubMed:9361298, ECO:0000269|PubMed:9452025, ECO:0000269|PubMed:9452099, ECO:0000269|PubMed:9469569, ECO:0000269|PubMed:9633821, ECO:0000269|PubMed:9818870, ECO:0000269|PubMed:9856562, ECO:0000269|Ref.12}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Dejerine-Sottas syndrome (DSS) [MIM:145900]: A severe degenerating neuropathy of the demyelinating Charcot-Marie-Tooth disease category, with onset by age 2 years. Characterized by motor and sensory neuropathy with very slow nerve conduction velocities, increased cerebrospinal fluid protein concentrations, hypertrophic nerve changes, delayed age of walking as well as areflexia. There are both autosomal dominant and autosomal recessive forms of Dejerine-Sottas syndrome. {ECO:0000269|PubMed:15947997}. Note=The gene represented in this entry may act as a disease modifier.;
Pathway
Neural Crest Differentiation;Common Pathways Underlying Drug Addiction;Calcium Regulation in the Cardiac Cell;Vesicle-mediated transport;Membrane Trafficking;Transport of connexins along the secretory pathway;Oligomerization of connexins into connexons;Gap junction assembly;Gap junction trafficking;Gap junction trafficking and regulation (Consensus)

Recessive Scores

pRec
0.440

Intolerance Scores

loftool
rvis_EVS
0.21
rvis_percentile_EVS
67.72

Haploinsufficiency Scores

pHI
0.824
hipred
Y
hipred_score
0.642
ghis
0.409

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.801

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Gjb1
Phenotype
homeostasis/metabolism phenotype; cellular phenotype; growth/size/body region phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); liver/biliary system phenotype; immune system phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); vision/eye phenotype; hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span);

Gene ontology

Biological process
cell-cell signaling;nervous system development;purine ribonucleotide transport;gap junction assembly;protein complex oligomerization;transmembrane transport;epididymis development
Cellular component
endoplasmic reticulum membrane;connexin complex;integral component of membrane;lateral plasma membrane
Molecular function
gap junction channel activity;protein homodimerization activity